1. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up
- Author
-
Sara Conti, Fabiana Madotto, Maria L Romano, Pietro Ferrara, Riccardo Polosa, Domenico Ponticelli, Beniamino Schiavone, Ippazio Cosimo Antonazzo, Lorenzo G. Mantovani, Giovanni Della Ragione, Mario Borrelli, Andrea Vitale, Ponticelli, D, Madotto, F, Conti, S, Antonazzo, I, Vitale, A, Della Ragione, G, Romano, M, Borrelli, M, Schiavone, B, Polosa, R, Ferrara, P, and Mantovani, L
- Subjects
medicine.medical_specialty ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,Im - Commentary ,Health Personnel ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Population ,Serology ,Internal medicine ,Health care ,Internal Medicine ,medicine ,Humans ,RNA, Messenger ,education ,Adverse effect ,BNT162 Vaccine ,education.field_of_study ,BNT162b2 vaccine ,SARS-CoV-2 ,business.industry ,COVID-19 ,Immunization ,Healthcare worker ,Emergency Medicine ,business ,Follow-Up Studies ,Month follow up - Abstract
This study investigated the response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers (HCWs) in an Italian teaching hospital. 444 participants were surveyed with either multiple RT-PCR assays for detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs or serology testing for the research of virus-specific immunoglobulins. Adverse events following immunization (AEFI) were reported. Two weeks after the first dose anti-SARS-CoV-2 antibodies exceeded reactivity cut-off in 82.5% the participants. Four HCWs tested positive at nasopharyngeal swab after 3 months. More than three-quarters reported AEFIs. Our findings offer an insight regarding the vaccine response after 3 months from its administration, with a special focus on effectiveness data, as well as the type and number of AEFIs complained by HCW recipients. The presented study may serve as reference for future research which will be necessary to explore the long-term safety of this vaccine, especially in population at high risk for infection, such as HCWs.
- Published
- 2021